These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 26293476)

  • 1. Design of inhibitors of BCRP/ABCG2.
    Juvale K; Wiese M
    Future Med Chem; 2015 Aug; 7(12):1521-7. PubMed ID: 26293476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ABCG2: recent discovery of potent and highly selective inhibitors.
    Lecerf-Schmidt F; Peres B; Valdameri G; Gauthier C; Winter E; Payen L; Di Pietro A; Boumendjel A
    Future Med Chem; 2013 Jun; 5(9):1037-45. PubMed ID: 23734686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Symmetric bis-chalcones as a new type of breast cancer resistance protein inhibitors with a mechanism different from that of chromones.
    Winter E; Devantier Neuenfeldt P; Chiaradia-Delatorre LD; Gauthier C; Yunes RA; Nunes RJ; Creczynski-Pasa TB; Di Pietro A
    J Med Chem; 2014 Apr; 57(7):2930-41. PubMed ID: 24611893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2).
    Juvale K; Gallus J; Wiese M
    Bioorg Med Chem; 2013 Dec; 21(24):7858-73. PubMed ID: 24184213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCRP/ABCG2 inhibitors: a patent review (2009-present).
    Wiese M
    Expert Opin Ther Pat; 2015; 25(11):1229-37. PubMed ID: 26291461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
    Pick A; Wiese M
    ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein.
    Juvale K; Pape VF; Wiese M
    Bioorg Med Chem; 2012 Jan; 20(1):346-55. PubMed ID: 22112540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2.
    Han B; Zhang JT
    Curr Med Chem Anticancer Agents; 2004 Jan; 4(1):31-42. PubMed ID: 14754410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human ABC transporter ABCG2 in cancer chemotherapy: drug molecular design to circumvent multidrug resistance.
    Ishikawa T; Saito H; Hirano H; Inoue Y; Ikegami Y
    Methods Mol Biol; 2012; 910():267-78. PubMed ID: 22821599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
    Zhang H; Wang YJ; Zhang YK; Wang DS; Kathawala RJ; Patel A; Talele TT; Chen ZS; Fu LW
    Cancer Lett; 2014 Aug; 350(1-2):61-8. PubMed ID: 24747122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
    Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo.
    Wang XK; To KK; Huang LY; Xu JH; Yang K; Wang F; Huang ZC; Ye S; Fu LW
    Oncotarget; 2014 Dec; 5(23):11971-85. PubMed ID: 25436978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
    Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
    Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein.
    Valdameri G; Genoux-Bastide E; Peres B; Gauthier C; Guitton J; Terreux R; Winnischofer SM; Rocha ME; Boumendjel A; Di Pietro A
    J Med Chem; 2012 Jan; 55(2):966-70. PubMed ID: 22165858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
    Köhler SC; Wiese M
    J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
    Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
    Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Piperazinobenzopyranones and phenalkylaminobenzopyranones: potent inhibitors of breast cancer resistance protein (ABCG2).
    Boumendjel A; Nicolle E; Moraux T; Gerby B; Blanc M; Ronot X; Boutonnat J
    J Med Chem; 2005 Nov; 48(23):7275-81. PubMed ID: 16279786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
    Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2.
    Juvale K; Stefan K; Wiese M
    Eur J Med Chem; 2013 Sep; 67():115-26. PubMed ID: 23851114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scaffold identification of a new class of potent and selective BCRP inhibitors.
    Marighetti F; Steggemann K; Karbaum M; Wiese M
    ChemMedChem; 2015 Apr; 10(4):742-51. PubMed ID: 25735648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.